Approvals For Stronger NSAIDs Label Warning About Risks During Late Pregnancy Begin In US
Executive Summary
FDA since late October has sent approvals to firms which had submitted proposals for updates under the “If pregnant or breast-feeding” warning on their OTC NDAID DFls. First approval, dated 21 October, went to Bionpharma for its 200-mg ibuprofen tablets it provides for private label and store brand customers.
You may also be interested in...
EU Regulatory News Round Up: NSAIDs During Pregnancy, Estragole Excipients, ePIs
CMDh receives applications to change how NSAIDs are recommended for use during pregnancy; HMPC warns against use of estragole-containing excipients in herbals; EMA adopts new EU common standard for electronic product information on medicines marketed within the region.
NSAIDs Marketed In US Will Have Stronger Label Warning About Risks During Late Pregnancy
In Drug Safety Communication, FDA says it is requiring labeling changes for Rx as well as OTC NSAIDs due to risk of rare but serious kidney problems in an unborn baby.
FDA Wants Stronger Cardiovascular Warning For OTC NSAIDs
The agency says it will require stronger warnings about cardiovascular risks on prescription NSAIDS’ Drug Facts labels, but will request that OTC NSAID labels also are changed.